2DE0 Stoklara Genel Bakış A clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Daha fazla detay
Risk Analizi + 2 daha fazla risk
Tüm Risk Kontrollerini Gör {"enabled":false,"variant":{"name":"disabled","enabled":false},"ready":false,"error":null}
Düşüncelerinizi, bağlantılarınızı ve şirket anlatımınızı yakalayın
Fiyat Geçmişi ve Performans
Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti Genprex Tarihsel hisse senedi fiyatları Güncel Hisse Fiyatı US$6.50 52 Haftanın En Yüksek Seviyesi US$37.82 52 Haftanın En Düşük Seviyesi US$6.50 Beta -0.63 1 Aylık Değişim 0% 3 Aylık Değişim -15.93% 1 Yıllık Değişim -76.93% 3 Yıllık Değişim -94.75% 5 Yıllık Değişim -89.44% Halka arzdan bu yana değişim -98.60%
Son Haberler & Güncellemeler
Genprex, Inc. Announces First Patient Has Been Enrolled and Dosed in the Phase 2 Expansion Portion of the Company’S Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy Jan 24
Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer Dec 16
Genprex, Inc. Receives Notice from Nasdaq Regarding Non-Compliance with Stockholders' Equity Requirement Nov 20
Genprex, Inc. Receives Safety Review Committee Approval to Advance to Highest Dose Group in Phase 1 Portion of Acclaim-3 Clinical Trial of Reqorsa Gene Therapy in Combination with Tecentriq in Extensive Stage Small Cell Lung Cancer Oct 15
Genprex Receives Non-Compliance Notice from Nasdaq Regarding Minimum Bid Price Requirement Sep 28 Genprex, Inc. Announces Positive Clinical Study Updates from Acclaim-1 and Acclaim-3 Phase 1/2 Clinical Trials in Lung Cancer Daha fazla güncelleme görün
Genprex, Inc. Announces First Patient Has Been Enrolled and Dosed in the Phase 2 Expansion Portion of the Company’S Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy Jan 24
Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer Dec 16
Genprex, Inc. Receives Notice from Nasdaq Regarding Non-Compliance with Stockholders' Equity Requirement Nov 20
Genprex, Inc. Receives Safety Review Committee Approval to Advance to Highest Dose Group in Phase 1 Portion of Acclaim-3 Clinical Trial of Reqorsa Gene Therapy in Combination with Tecentriq in Extensive Stage Small Cell Lung Cancer Oct 15
Genprex Receives Non-Compliance Notice from Nasdaq Regarding Minimum Bid Price Requirement Sep 28 Genprex, Inc. Announces Positive Clinical Study Updates from Acclaim-1 and Acclaim-3 Phase 1/2 Clinical Trials in Lung Cancer Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa Immunogene Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer Genprex, Inc Announces Executive Changes
Genprex, Inc., Annual General Meeting, Jun 18, 2024 May 01 Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer Genprex, Inc. has completed a Follow-on Equity Offering. Mar 26
Genprex, Inc. has filed a Follow-on Equity Offering. Mar 21
Genprex, Inc. has filed a Follow-on Equity Offering. Mar 20
Genprex, Inc. Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers Mar 12
Genprex, Inc. Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators Feb 07
Genprex, Inc. Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa Therapy in Combination with Tagrisso to Treat Non-Small Cell Lung Cancer Feb 05
New major risk - Market cap size Feb 03
No longer forecast to breakeven Jan 23
Genprex, Inc. to Present Data on the Use of Reqorsa for the Treatment of Lung Cancers At 2023 Aacr-Nci-Eortc International Conference on Molecular Targets and Cancer Therapeutics Oct 05
Genprex Receives Non-Compliance Notice From Nasdaq Sep 02
Genprex Appoints Suzanne Thornton-Jones as Senior Vice President, Regulatory Affairs Aug 23
Genprex, Inc. announced delayed 10-Q filing Aug 17
Genprex, Inc. Receives Fast Track Designation from the FDA for Its Small Cell Lung Cancer Drug Candidate Jul 12
Genprex, Inc. Grants Chinese Patent for REQORSA(R) Immunogene Therapy in Combination with PD-1 Antibodies to Treat Cancers Jul 06
Genprex Receives U.S. FDA Fast Track Designation for REQORSA Immunogene Therapy in Combination with Tecentriq for the Treatment of Small Cell Lung Cancer Jun 29
Genprex, Inc. Receives Safety Review Committee Approval to Advance to Phase 2 Expansion Portion of Acclaim-1 Clinical Trial of REQORSA(R) in Combination with Tagrisso(R) in Advanced Non-Small Cell Lung Cancer May 31
Genprex, Inc. Publishes Positive Clinical Data from Phase 1 Portion of Acclaim-1 Clinical Trial Evaluating Reqorsa Immunogene Therapy in Non-Small Cell Lung Cancer May 26 Genprex, Inc. announced delayed 10-Q filing May 17
No longer forecast to breakeven Apr 02
High number of new directors Mar 24
High number of new and inexperienced directors Feb 17
Genprex Receives Safety Review Committee Approval to Proceed to Final Cohort in Acclaim-1 Phase 1 Dose Escalation Trial of REQORSA(R) in Combination with Tagrisso(R) in Advanced Non-Small Cell Lung Cancer Dec 15
High number of new and inexperienced directors Dec 13
High number of new and inexperienced directors Nov 21
Genprex Announces Safety Review Committee Approves Dose Escalation in Acclaim-1 Phase 1/2 Trial of REQORSA™ in Combination with Tagrisso® in Non-Small Cell Lung Cancer Aug 16
High number of new and inexperienced directors Apr 28
Genprex, Inc. Announces the Opening for Enrollment of its Phase 1/2 Acclaim-2 Clinical Trial of REQORSA™ Immunogene Therapy in Combination With Keytruda® to Treat Non-Small Cell Lung Cancercer Apr 01
Genprex, Inc. Announces First Patient Dosed in Phase 1/2 Acclaim-1 Clinical Trial of REQORSA Immunogene Therapy in Combination with Tagrisso to Treat Non-Small Cell Lung Cancer Mar 04
Genprex, Inc. Announces First Patient Dosed in Phase 1/2 Acclaim-1 Clinical Trial of REQORSA Immunogene Therapy in Combination with Tagrisso to Treat Non-Small Cell Lung Cancer Mar 03
Genprex, Inc. Announces Positive Preclinical Data for Use of Genprex’s ONCOPREX® Nanoparticle Delivery System for Delivery of FAS DNA Plasmid to Treat Metastatic Colorectal Cancer Jan 28
Genprex, Inc. to Accelerate Opening of Acclaim-1 Clinical Trial Sites Jan 12
Genprex Expands Gene Therapy Oncology Pipeline to Include Small Cell Lung Cancer Jan 06
Genprex Receives U.S. FDA Fast Track Designation for REQORSA™ Immunogene Therapy in Combination With Keytruda® for the Treatment of Non-Small Cell Lung Cancer Jan 05 Genprex, Inc.(NasdaqCM:GNPX) dropped from Russell 3000E Index
Genprex Announces Initiation of its Phase 1/2 Acclaim-1 Clinical Trial for REQORSA™ Immunogene Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer Following FDA Review Jun 24
Forecast to breakeven in 2024 Jun 11
Genprex Announces Centralized Institutional Review Board Approval for Acclaim-1 Clinical Trial in Non-Small Cell Lung Cancer May 06
Genprex Initiates Site Recruitment for Acclaim-2 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer May 05
Genprex, Inc. Announces Formation of Clinical Advisory Board Feb 09
Genprex, Inc. Achieves Major Manufacturing Milestone for REQORSA™ Immunogene Therapy for Upcoming Trials to Treat Non-Small Cell Lung Cancer Jan 14
Genprex, Inc. Completes Manufacturing Scale-Up for Clinical-Grade Production of REQORSA™ Immunogene Therapy for Upcoming Acclaim-1 and Acclaim-2 Clinical Trials For Lung Cancer Dec 23
Genprex, Inc Completes Manufacturing Technology Transfer for Novel Gene Therapy Dec 10
Genprex Initiates Site Recruitment for Acclaim-1 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer Dec 03
Genprex, Inc. Appoints George K. Gittes to Its Scientific Advisory Board Nov 11
Genprex, Inc. Promotes Eric Chapdelaine to Vice President of Manufacturing Oct 27
Genprex, Inc. Names Thomas C. Gallagher, Esq. as Senior Vice President of Intellectual Property and Licensing Sep 22 Hissedar Getirileri 2DE0 DE Biotechs DE Pazar 7D 0% 1.2% 2.3% 1Y -76.9% -5.6% 16.7%
Hissedar getirilerinin tamamını görün
Getiri vs. Endüstri: 2DE0 geçen yıl % -5.6 oranında getiri sağlayan German Biotechs sektörünün gerisinde kaldı.
Getiri vs Piyasa: 2DE0 geçen yıl % 16.7 oranında getiri sağlayan German Piyasasının altında performans gösterdi.
Fiyat Oynaklığı Is 2DE0's price volatile compared to industry and market? 2DE0 volatility 2DE0 Average Weekly Movement n/a Biotechs Industry Average Movement 5.7% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.5%
İstikrarlı Hisse Senedi Fiyatı: 2DE0 hisse senedi fiyatı, son 3 ayda German piyasasına kıyasla dalgalı seyretti.
Zaman İçindeki Volatilite: 2DE0 'un son bir yıldaki oynaklık değişimini belirlemek için Yetersiz veri .
Şirket Hakkında Daha fazla göster Genprex, Inc. Temel Bilgiler Özeti Genprex'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır? 2DE0 temel i̇stati̇sti̇kler Piyasa değeri €4.08m Kazançlar(TTM ) -€28.78m Gelir(TTM ) n/a
Kazanç ve Gelir En son kazanç raporundan temel karlılık istatistikleri (TTM) 2DE0 gelir tablosu (TTM ) Gelir US$0 Gelir Maliyeti US$0 Brüt Kâr US$0 Diğer Giderler US$30.86m Kazançlar -US$30.86m
Şirket Analizi ve Finansal Veri Durumu Veri Son Güncelleme (UTC saati) Şirket Analizi 2024/04/30 03:35 Gün Sonu Hisse Fiyatı 2024/02/01 00:00 Kazançlar 2023/12/31 Yıllık Kazançlar 2023/12/31
Veri Kaynakları Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC 'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
Paket Veri Zaman Çerçevesi Örnek ABD Kaynağı * Şirket Finansalları 10 yıl Gelir tablosu Nakit akış tablosu Bilanço Analist Konsensüs Tahminleri +3 yıl Finansal tahminler Analist fiyat hedefleri Piyasa Fiyatları 30 yıl Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler Sahiplik 10 yıl En büyük hissedarlar İçeriden öğrenenlerin ticareti Yönetim 10 yıl Liderlik ekibi Yönetim Kurulu Önemli Gelişmeler 10 yıl
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin .
Analiz Modeli ve Kar Tanesi Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube' da eğitimlerimiz bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github 'da mevcuttur.
Analist Kaynakları Genprex, Inc. 1 Bu analistlerden 2, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
Analist Kurum James Molloy Alliance Global Partners
